Is a Cure for Blood Cancer Around the Corner?

New Leukemia Research in Phase I/IIa Clinical Trial

Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run by pharma mogul Mori Arkin, and US-based venture firm Primera Capital. The money will be used to fund an advanced phase study of the company’s lead product, Astarabine, for the treatment of AML — acute myeloid leukemia, one of the two most common forms of the disease. –